Andrew Shutterly - Jun 26, 2024 Form 3 Insider Report for Altimmune, Inc. (ALT)

Role
Acting Chief Financial Officer. Exhibit 24 - Power of Attorney.
Signature
/s/ Vipin K. Garg, as Attorney-in-Fact
Stock symbol
ALT
Transactions as of
Jun 26, 2024
Transactions value $
$0
Form type
3
Date filed
7/1/2024, 06:00 PM
Next filing
Aug 1, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ALT Common Stock, par value $0.0001 10.1K Jun 26, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ALT Stock Option (Right to Buy) Jun 26, 2024 Common Stock, par value $0.0001 20K $7.05 Direct F1
holding ALT Stock Option (Right to Buy) Jun 26, 2024 Common Stock, par value $0.0001 25K $12.88 Direct F2
holding ALT Stock Option (Right to Buy) Jun 26, 2024 Common Stock, par value $0.0001 15K $4.48 Direct F3
holding ALT Stock Option (Right to Buy) Jun 26, 2024 Common Stock, par value $0.0001 12K $9.28 Direct F4
holding ALT Restricted Stock Units Jun 26, 2024 Common Stock, par value $0.0001 11.3K $0.00 Direct F5
holding ALT Restricted Stock Units Jun 26, 2024 Common Stock, par value $0.0001 3K $0.00 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent of the shares underlying the option became vested and exercisable on March 17, 2023 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following March 17, 2023, subject to the reporting person's continued service through the applicable vesting date.
F2 Twenty-five percent of the shares underlying the option became vested and exercisable on January 30, 2024 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following January 30, 2024, subject to the reporting person's continued service through the applicable vesting date.
F3 Twenty-five percent of the shares underlying the option became vested and exercisable on May 22, 2024 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following May 22, 2024, subject to the reporting person's continued service through the applicable vesting date.
F4 Twenty-five percent of the shares underlying the option become vested and exercisable on January 25, 2025 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following January 25, 2025, subject to the reporting person's continued service through the applicable vesting date.
F5 The RSUs will vest in equal annual installments of 3,750 shares on January 30, 2025, January 30, 2026 and January 30, 2027, subject to the reporting person's continued service through the applicable date, and have no expiration date.
F6 The RSUs become vested and exercisable over four 4 years with 25% of the shares vesting on January 25, 2025, with the remainder vesting in equal annual installments for the following three years, subject to the reporting person's continued service through the applicable date, and have no expiration date.

Remarks:

Acting Chief Financial Officer. Exhibit 24 - Power of Attorney.